NRXP — NRX Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $107.81m
- $81.53m
- $1.23m
U.S. STOCKS ON THE MOVE-Lululemon, Copper miners, Gold miners
NRx Pharma gains on plans to submit marketing application for depression drug
Brief: Nrx Pharmaceuticals Inc Reports Potential NDA Filing For Nrx-100 In 2024
Brief: Nrx Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy And Safety Of Intravenous Ketamine For The Treatment Of Suicidal Bipolar Depression
Brief: NRX Pharmaceuticals Announces Agreement With Lifesci Associates To Provide Financial Services And Support
Brief: NRX Pharmaceuticals Announces Potent Antibacterial Activity Of Nrx-101 Against Common, Antibiotic Resistant Urinary Pathogens
Brief: NRx Pharmaceuticals Announces Submission Of An Investigational New Drug Application For NRX-101 In The Treatment Of Chronic Pain
Brief: NRx Pharmaceuticals Announces Definitive Purchase Agreement For Preferred Shares At $0.40 Per Share
NRX Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Nrx Pharmaceuticals Announces Licensure Of A U.S. Patent To Support Use Of Nrx-101 For Chronic Pain
Brief: Nrx Pharmaceuticals Inc Got Notice From Nasdaq That Co Was Not In Compliance With Nasdaq Listing Rule
Brief: NRx Pharmaceuticals Announces Closing Of $6.28 Mln Registered Direct Offering
Brief: NRx Pharmaceuticals, Lotus Pharmaceuticals And Alvogen To Collaborate To Develop And Commercialize NRX-101
U.S. RESEARCH ROUNDUP-Empire State, Integra Lifesciences, Lowe's Companies
NRX Pharmaceuticals rises on smaller Q1 net loss
Brief: NRX Pharmaceuticals Reports First Quarter 2023 Financial Results
NRX Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
NRX Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Nrx Pharmaceuticals Received Notice Of Delisting From Nasdaq